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Natalizumab is a disease-modifying therapy (DMT) used in relapsing-remitting 
multiple sclerosis (RRMS), licenced for use in patients with highly-active disease. It 
is an α4-integrin receptor antagonist that decreases activated T cell migration across 
the blood-brain barrier.1 Natalizumab carries a risk of progressive multifocal 
leukoencephalopathy (PML) - a risk that increases with duration of treatment; John 
Cunningham Virus (JCV) seropositivity and higher index values; and prior use of 
immunosuppression.1 Patients may choose to withdraw from natalizumab to mitigate 
PML risk, or less commonly when natalizumab fails to control disease activity, or is 
poorly tolerated. Fingolimod has been commonly used as an option in those making 
the switch from natalizumab, but is associated with high rates of breakthrough 
clinical and/or radiological disease activity, although the risks may be lower with 
shorter washout periods.2 Rituximab has been suggested as an alternative to 
fingolimod in patients discontinuing natalizumab due to high PML risk, however, 
rituximab is not licenced for the treatment of RRMS and is not available in some 
countries for this indication.3  
Alemtuzumab is a monoclonal antibody that binds to the CD52 surface protein on T 
and B lymphocytes, resulting in their depletion with subsequent re-population, with 
comparable efficacy to natalizumab.1 Switching to alemtuzumab might be an 
alternative to fingolimod in patients stopping natalizumab but there is a paucity of 
clinical and safety data to guide this transition. Here we present a single-centre 
experience in switching from natalizumab to alemtuzumab in RRMS.  
 
Methods 
We retrospectively identified patients from the National Hospital for Neurology and 
Neurosurgery who switched from natalizumab to alemtuzumab from May 2015 to 
February 2018. We extracted data from the medical records: demographic 
characteristics, duration of natalizumab use, drug washout period, cerebrospinal fluid 
(CSF) examination results, JCV serology, clinical disease activity (relapses) before 
and after commencing alemtuzumab, Expanded Disability Status Scale (EDSS) 
scores, MRI measures of disease activity (number of new T2 and gadolinium 
enhancing lesions) pre- and post- alemtuzumab, and adverse events. All data are 
presented as mean (standard deviation) unless otherwise stated.  
The study was approved by the Queen Square Quality and Safety Committee, 
National Hospital for Neurology & Neurosurgery.  
 
Results 
19 patients (mean age 38 [11] years, 10 (53%) female) were identified who switched 
from natalizumab to alemtuzumab. Mean disease duration from onset at the time of 
receiving alemtuzumab was 10 (7) years and the median number of natalizumab 
infusions prior to switching was 41 (range 8-95). Natalizumab was the first DMT 
taken in 5 (26%) patients. The annualised relapse rate (ARR) in the 12 months prior 
to commencing alemtuzumab was 0.74 and median EDSS was 6.5 (1.5-8.0).  
The reasons for changing treatment were: PML risk (n=11), lack of efficacy (n=6), 
tolerability (n=1) and family planning (n=1).  Fifteen (79%) patients were JCV-
positive; all JCV-positive patients had an MRI brain and 12/15 (80%) had CSF to 
check JCV-PCR before starting alemtuzumab. The mean washout period in the 
entire cohort was 128 days (median 120; range 28–307). The washout period was 
≥12 weeks in 17 (89%) patients. 
18/19 patients had at least 12 months clinical follow-up after starting alemtuzumab 
(median 22; [range 8-39]). Sixteen relapses occurred in 10/19 (53%) (figure 1), 
including 5/6 (83%) who switched from natalizumab to alemtuzumab because of 
ongoing disease activity. There was no significant difference in the ARR in the 12 
months pre- and post alemtuzumab in those switching due to lack of efficacy (1.83 
vs 0.67, p = 0.07) or in those switching with inactive disease (0.23 vs 0.15, p=0.72). 
EDSS scores remained stable in 12 patients, improved in 3 patients and worsened in 
3 patients; follow up EDSS score was not available for 1 patient. Of the 17 patients 
who have had follow up MRI, 5/17 (29%) demonstrated new MRI activity: 3 patients 
had new T2 lesions at the 12 month follow up MRI (after starting alemtuzumab) and 
2 patients developed a single gadolinium enhancing lesion seen 6 months post 
second cycle of alemtuzumab.  
The mean lymphocyte count 1 month after the first and second cycle of 
alemtuzumab was 0.39 (0.34) and 0.37 (0.20) respectively. In patients who 
experienced a relapse post alemtuzumab versus those who had stable disease, 
there was no difference in the mean lymphocyte count 1 month after the first (0.39 vs 
0.40, p = 0.60) or second cycles (0.44 vs 0.23, p = 0.06).  
Adverse events were in keeping with the known side effect profile of alemtuzumab. 
17/19 (89%) had infusion reactions during at least 1 of the alemtuzumab cycles and 
2 patients had urticaria and erythema multiforme respectively. 10/19 (53%) 
developed an infection during the post-alemtuzumab follow-up period with the most 
common being urinary tract infections (14 infections) and upper respiratory tract 
infections (5 infections). There was one case of herpes zoster opthalmicus. There 
were no cases of secondary autoimmunity to date, and no PML.  
Discussion 
Our series of consecutive patients suggests that alemtuzumab may be a reasonable 
option in patients stopping natalizumab, especially in patients with stable disease 
who are changing their therapy because of PML risk. In such patients, the goal is to 
minimise the risk of carry-over PML whilst maintaining control of disease activity. 
Giavannoni and colleagues provide an approach to managing the switch from 
natalizumab to alemtuzumab by using an initial MRI and CSF JCV DNA-PCR to 
exclude subclinical PML (small risk of false negative results) followed by a direct 
switch, 3-6 month washout before commencing alemtuzumab or starting an oral 
bridging agent within 2-4 weeks and using this for 6-12 months before starting 
alemtuzumab. 4 Using MRI and CSF JCV-PCR to exclude subclinical PML prior to 
switching, and a median washout period of 120 days, there have been no cases of 
PML in our cohort. Our experience is similar to Malucchi and colleagues, who 
reported on 16 patients with stable RRMS, switching to alemtuzumab due to PML 
risk after a median washout period of 70 days (41-99). At 12 months follow-up, there 
were no cases of PML or breakthrough disease activity.5  
Our results suggest that alemtuzumab may not prevent breakthrough disease activity 
in patients who discontinued natalizumab because of lack of efficacy. Whilst there is 
a paucity of published data examining cohorts switching solely due to lack of 
efficacy,  Pfeuffer and colleagues in a retrospective analysis of 143 patients who 
switched from natalizumab to either fingolimod or alemtuzumab, suggest that 
patients switching to alemtuzumab had lower rates of disease activity compared to 
those switching to fingolimod.6 Previous studies examining washout periods when 
switching from natalizumab suggest that the risk of breakthrough disease activity 
increases with washout periods greater than 8-12 weeks.7,8 In our cohort, the high 
proportion of cases with breakthrough disease activity in those switching due to lack 
of efficacy is only partly explained by the duration of the washout. Recent work has 
also shed light on lymphocyte depletion following alemtuzumab administration, its 
potential link to anti-alemtuzumab antibodies and the impact this may have on 
breakthrough disease activity at an individual level.9,10 These factors may have 
played a role in the development of breakthrough disease activity in our cohort given 
the trend towards higher lymphocyte counts post second cycle in those who 
experienced a relapse post alemtuzumab. The small sample sizes made it difficult to 
detect differences in post-alemtuzumab lymphocyte counts between these two 
groups. Other options such as autologous haematopoietic stem cell transplantation 
may need to be considered in patients who fail natalizumab because of ongoing 
disease activity.3 Limitations of our study include the small sample size and 
retrospective study design. Larger prospective studies are required to further assess 
the efficacy and safety of alemtuzumab in patients previously treated with 
natalizumab. 
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